Viaskin Peanut 250µg
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Peanut Allergy
Conditions
Peanut Allergy
Trial Timeline
Jan 23, 2017 → Mar 1, 2023
NCT ID
NCT03013517About Viaskin Peanut 250µg
Viaskin Peanut 250µg is a phase 3 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is unknown. This product is registered under clinical trial identifier NCT03013517. Target conditions include Peanut Allergy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03013517 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Peanut Allergy